Sequential Anti-Angiogenic Therapy After Immunotherapy in Advanced Biliary Tract Cancer

NCT07025174 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

60

Enrollment

OTHER

Sponsor class

Conditions

Bile Duct Carcinoma
Gall Bladder Cancer
Biliary Tract Cancer
Cholangiocarcinoma

Interventions

DRUG: PD-1/CTLA-4 Dual Functional Antibody
DRUG: Gemcitabine, Cisplatin
DRUG: Anlotinib
DRUG: Oxaliplatin + 5-Fluorouracil/Leucovorin

Sponsor

First Affiliated Hospital of Zhejiang University